SlideShare a Scribd company logo
1 of 17
PULMONARY
FUNCTION
TEST
DR. GANESH BR
PFT
 Spirometry
 – Before and after bronchodilator
 – Sitting and supine
 • Lung volumes
 • Diffusion capacity (DLCO)
 • Methacholine challenge
 • Maximum voluntary ventilation (MVV)
 • Maximum inspiratory and expiratory pressures
(MIPS/MEPS)
 • Pulse oximetry
 • Arterial blood gases (ABGs)
 • Six minute walk test
 • Cardiopulmonary exercise test (CPET)
 • Exhaled nitric oxide (FENO)
EQUIPMENT OF PFT
FLOW VOLUME LOOP
PARAMETERS
 FVC: maximum amount of air exhaled after a maximal
inhalation
 If normal:
 Elasticity is fairly normal (normal lung tissue)
 Thoracic cage (configuration of thoracic spine/ribs) is normal
 Respiratory muscles aren’t too weak
 If low, suggests one or more of the above is a problem
(restrictive disorder)
 FEV1: amount of air exhaled in the first second as forcefully as
possible from a full lung
 Measuring the speed of the air being exhaled can provide a
window to the airways -volume exhaled in the first second is a
measure of speed (litres/second)
 (FEV1) reduced speed indicates ‘obstructed’ or narrowed
airways
 FEV1/FVC ratio: identification of airflow obstruction:– <70% of
predicted
WHATS NORMAL?
 Gender, Age, Height, Race
 Test data collected on a large number of ‘normal’ individuals:
 – No history of lung disease
 – No symptoms
 – Normal chest X-ray
 – Normal EKG
 Pooled data used to relate lung function to characteristics
most closely related to lung function
 Predicted value (% of predicted): Age and height are entered
into an equation to calculate the:-
 average predicted value for an individual = middle of the
normal range
 Lower limit of normal (LLN): Another equation is used to
define the ‘Lower Limit of Normal’ = lowest value considered
normal for an individual
STEP BY STEP
INTERPRETATION
 Step 1: FEV1/FVC ratio
 FEV1/FVC <70% (or less than the LLN): Obstructive pattern
(COPD, asthma)
 ≥ 70%: Normal or Restrictive disease
 Step 2:
 Severity of obstruction (GOLD Criteria for COPD)
 FEV1 80 - 100% predicted: Mild (Stage I)
 FEV1 50 - <80% predicted: Moderate (Stage II)
 FEV1 30 -<50% predicted: Severe (Stage III)
 FEV1 < 30% predicted: Very severe (Stage IV)
 FEV1< 50% with right side heart failure: Very severe (Stage IV)
 Severity of obstruction (ATS General Criteria):
keep it simple
 FEV1 over 70% predicted: MILD
 FEV1 60-70% predicted: MODERATE
 FEV1 50-60% predicted: MODERATELY SEVERE
 FEV1 35-50% predicted: SEVERE
 FEV1 < 35% predicted: VERY SEVERE
 Step 3: Bronchodilator response:
 ≥ 12% increase AND an absolute improvement of at
least 200 ml after inhaling a beta agonist
 FEV1, OR FVC is considered a significant
response
 Step 4: Total Lung Capacity (TLC) (Normal range: 80 - 120% of
predicted)
 TLC > 120% = Hyperinflation
 TLC < 80% = Restrictive disease (ATS criteria for severity): keep
it simple
 70-80 % predicted: mild
 60-70% predicted: moderate
 50-60% predicted: moderately severe
 < 50% predicted: severe
 Step 5: RV/TLC ratio (Normal range: < 35% or < predicted)
 RV/TLC > 35% or > predicted indicates Air trapping
 Step 6: DLCO (Normal range: 80- 120% of predicted)
 In obstructive disease:
 Decreased in Emphysema
 Normal in chronic bronchitis
 Normal or increased in Asthma
 In restrictive disease:
 Decreased in parenchymal disease
 Normal in non-parenchymal (e.g. chest wall) restriction
NORMAL EARLY ON COAD FLAO ETLAO RES
DISEASE
PFT DETAIL.pptx

More Related Content

Similar to PFT DETAIL.pptx

Anaecon India - Spirometery
Anaecon India - SpirometeryAnaecon India - Spirometery
Anaecon India - Spirometery
Sarthak Jain
 
Clinical application of pulmonary function tests.pptm1
Clinical application of pulmonary function tests.pptm1Clinical application of pulmonary function tests.pptm1
Clinical application of pulmonary function tests.pptm1
Gamal Agmy
 
Diagnosis of COPD
Diagnosis of COPDDiagnosis of COPD
Diagnosis of COPD
Gamal Agmy
 

Similar to PFT DETAIL.pptx (20)

Pulmonary function testing
Pulmonary function testingPulmonary function testing
Pulmonary function testing
 
Bài Giảng Hô Hấp Ký
Bài Giảng Hô Hấp KýBài Giảng Hô Hấp Ký
Bài Giảng Hô Hấp Ký
 
Anaecon India - Spirometery
Anaecon India - SpirometeryAnaecon India - Spirometery
Anaecon India - Spirometery
 
Clinical application of pulmonary function tests.pptm1
Clinical application of pulmonary function tests.pptm1Clinical application of pulmonary function tests.pptm1
Clinical application of pulmonary function tests.pptm1
 
My presentation
My presentationMy presentation
My presentation
 
simplyfying spirometry
simplyfying spirometry simplyfying spirometry
simplyfying spirometry
 
Spirometry
 Spirometry Spirometry
Spirometry
 
Common pulmonary functions and interpretation
Common pulmonary functions and interpretationCommon pulmonary functions and interpretation
Common pulmonary functions and interpretation
 
Diagnosis of COPD
Diagnosis of COPDDiagnosis of COPD
Diagnosis of COPD
 
Pft 10.12.14
Pft 10.12.14Pft 10.12.14
Pft 10.12.14
 
Spirometry by dr tasleem
Spirometry by dr tasleemSpirometry by dr tasleem
Spirometry by dr tasleem
 
Pulmonary functions Tests
Pulmonary functions TestsPulmonary functions Tests
Pulmonary functions Tests
 
Assessment of lung function before surgery.dr quiyum
Assessment of lung function before surgery.dr quiyumAssessment of lung function before surgery.dr quiyum
Assessment of lung function before surgery.dr quiyum
 
COPD Lecture 9 spirometry of obstructive lung diseases
COPD Lecture 9  spirometry of obstructive lung diseasesCOPD Lecture 9  spirometry of obstructive lung diseases
COPD Lecture 9 spirometry of obstructive lung diseases
 
Mechanical ventilation jr nov 2017
Mechanical ventilation   jr nov 2017Mechanical ventilation   jr nov 2017
Mechanical ventilation jr nov 2017
 
PFT
PFT PFT
PFT
 
Lung fuction tests
Lung fuction tests  Lung fuction tests
Lung fuction tests
 
PULMONARY FUNCTION TEST(PFT).pptx
PULMONARY FUNCTION TEST(PFT).pptxPULMONARY FUNCTION TEST(PFT).pptx
PULMONARY FUNCTION TEST(PFT).pptx
 
COPD (1).pptx
COPD (1).pptxCOPD (1).pptx
COPD (1).pptx
 
Pulmonary function testing
Pulmonary function testingPulmonary function testing
Pulmonary function testing
 

More from devanshi92 (14)

Energy Expenditure.ppt
Energy Expenditure.pptEnergy Expenditure.ppt
Energy Expenditure.ppt
 
HUMIDIFICATION AND NEBULIZATION.pptx
HUMIDIFICATION AND NEBULIZATION.pptxHUMIDIFICATION AND NEBULIZATION.pptx
HUMIDIFICATION AND NEBULIZATION.pptx
 
'age related cardiopulmonary changes.pptx'.pptx
'age related cardiopulmonary changes.pptx'.pptx'age related cardiopulmonary changes.pptx'.pptx
'age related cardiopulmonary changes.pptx'.pptx
 
effect of ex on various systems , adaptations.pptx
effect of ex on various systems , adaptations.pptxeffect of ex on various systems , adaptations.pptx
effect of ex on various systems , adaptations.pptx
 
eye rehab.pptx
eye rehab.pptxeye rehab.pptx
eye rehab.pptx
 
ergonomics[1].pptx
ergonomics[1].pptxergonomics[1].pptx
ergonomics[1].pptx
 
REVIEW OF LITERATIRE 1 PG 2.pptx
REVIEW OF LITERATIRE 1 PG 2.pptxREVIEW OF LITERATIRE 1 PG 2.pptx
REVIEW OF LITERATIRE 1 PG 2.pptx
 
PATHOGENESIS AND MANAGEMENT OF ARDS-2.pptx
PATHOGENESIS AND MANAGEMENT OF ARDS-2.pptxPATHOGENESIS AND MANAGEMENT OF ARDS-2.pptx
PATHOGENESIS AND MANAGEMENT OF ARDS-2.pptx
 
bronchiectasis Presentation1.pptx
bronchiectasis Presentation1.pptxbronchiectasis Presentation1.pptx
bronchiectasis Presentation1.pptx
 
CHEST X-RAY F.pptx
CHEST X-RAY F.pptxCHEST X-RAY F.pptx
CHEST X-RAY F.pptx
 
BIOCHEMICAL INVESTIGATIONS.pptx
BIOCHEMICAL INVESTIGATIONS.pptxBIOCHEMICAL INVESTIGATIONS.pptx
BIOCHEMICAL INVESTIGATIONS.pptx
 
CHEST X-RAY SEMINAR FINAL.pdf
CHEST  X-RAY  SEMINAR  FINAL.pdfCHEST  X-RAY  SEMINAR  FINAL.pdf
CHEST X-RAY SEMINAR FINAL.pdf
 
exercise tolerance test.pptx
exercise tolerance test.pptxexercise tolerance test.pptx
exercise tolerance test.pptx
 
CARDIAC REHAB.pptx
CARDIAC REHAB.pptxCARDIAC REHAB.pptx
CARDIAC REHAB.pptx
 

Recently uploaded

Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
PECB
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
kauryashika82
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
Chris Hunter
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
MateoGardella
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
heathfieldcps1
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 

Recently uploaded (20)

Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writing
 

PFT DETAIL.pptx

  • 2. PFT  Spirometry  – Before and after bronchodilator  – Sitting and supine  • Lung volumes  • Diffusion capacity (DLCO)  • Methacholine challenge  • Maximum voluntary ventilation (MVV)  • Maximum inspiratory and expiratory pressures (MIPS/MEPS)  • Pulse oximetry  • Arterial blood gases (ABGs)  • Six minute walk test  • Cardiopulmonary exercise test (CPET)  • Exhaled nitric oxide (FENO)
  • 4.
  • 6.
  • 7. PARAMETERS  FVC: maximum amount of air exhaled after a maximal inhalation  If normal:  Elasticity is fairly normal (normal lung tissue)  Thoracic cage (configuration of thoracic spine/ribs) is normal  Respiratory muscles aren’t too weak  If low, suggests one or more of the above is a problem (restrictive disorder)
  • 8.  FEV1: amount of air exhaled in the first second as forcefully as possible from a full lung  Measuring the speed of the air being exhaled can provide a window to the airways -volume exhaled in the first second is a measure of speed (litres/second)  (FEV1) reduced speed indicates ‘obstructed’ or narrowed airways  FEV1/FVC ratio: identification of airflow obstruction:– <70% of predicted
  • 9. WHATS NORMAL?  Gender, Age, Height, Race  Test data collected on a large number of ‘normal’ individuals:  – No history of lung disease  – No symptoms  – Normal chest X-ray  – Normal EKG  Pooled data used to relate lung function to characteristics most closely related to lung function
  • 10.  Predicted value (% of predicted): Age and height are entered into an equation to calculate the:-  average predicted value for an individual = middle of the normal range  Lower limit of normal (LLN): Another equation is used to define the ‘Lower Limit of Normal’ = lowest value considered normal for an individual
  • 11. STEP BY STEP INTERPRETATION  Step 1: FEV1/FVC ratio  FEV1/FVC <70% (or less than the LLN): Obstructive pattern (COPD, asthma)  ≥ 70%: Normal or Restrictive disease  Step 2:  Severity of obstruction (GOLD Criteria for COPD)  FEV1 80 - 100% predicted: Mild (Stage I)  FEV1 50 - <80% predicted: Moderate (Stage II)  FEV1 30 -<50% predicted: Severe (Stage III)  FEV1 < 30% predicted: Very severe (Stage IV)  FEV1< 50% with right side heart failure: Very severe (Stage IV)
  • 12.  Severity of obstruction (ATS General Criteria): keep it simple  FEV1 over 70% predicted: MILD  FEV1 60-70% predicted: MODERATE  FEV1 50-60% predicted: MODERATELY SEVERE  FEV1 35-50% predicted: SEVERE  FEV1 < 35% predicted: VERY SEVERE
  • 13.  Step 3: Bronchodilator response:  ≥ 12% increase AND an absolute improvement of at least 200 ml after inhaling a beta agonist  FEV1, OR FVC is considered a significant response
  • 14.  Step 4: Total Lung Capacity (TLC) (Normal range: 80 - 120% of predicted)  TLC > 120% = Hyperinflation  TLC < 80% = Restrictive disease (ATS criteria for severity): keep it simple  70-80 % predicted: mild  60-70% predicted: moderate  50-60% predicted: moderately severe  < 50% predicted: severe  Step 5: RV/TLC ratio (Normal range: < 35% or < predicted)  RV/TLC > 35% or > predicted indicates Air trapping
  • 15.  Step 6: DLCO (Normal range: 80- 120% of predicted)  In obstructive disease:  Decreased in Emphysema  Normal in chronic bronchitis  Normal or increased in Asthma  In restrictive disease:  Decreased in parenchymal disease  Normal in non-parenchymal (e.g. chest wall) restriction
  • 16. NORMAL EARLY ON COAD FLAO ETLAO RES DISEASE